The stock of Lyra Therapeutics Inc (LYRA) has gone up by 438.78% for the week, with a 343.59% rise in the past month and a 154.42% rise in the past quarter. The volatility ratio for the week is 7.84%, and the volatility levels for the past 30 days are 6.47% for LYRA. . The simple moving average for the past 20 days is 315.86% for LYRA’s stock, with a 149.70% simple moving average for the past 200 days.
Is It Worth Investing in Lyra Therapeutics Inc (NASDAQ: LYRA) Right Now?
Company’s 36-month beta value is -0.01.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for LYRA is 1.12M, and currently, short sellers hold a 4.83% ratio of that floaft. The average trading volume of LYRA on June 02, 2025 was 69.15K shares.
LYRA) stock’s latest price update
Lyra Therapeutics Inc (NASDAQ: LYRA) has experienced a rise in its stock price by 401.62 compared to its previous closing price of 4.93. However, the company has seen a gain of 438.78% in its stock price over the last five trading days. finbold.com reported 2025-06-02 that Lyra Therapeutics (NASDAQ: LYRA) ‘s shares surged 550% in pre-market trading on Monday following a breakthrough in its drug trials.
Analysts’ Opinion of LYRA
Many brokerage firms have already submitted their reports for LYRA stocks, with Jefferies repeating the rating for LYRA by listing it as a “Hold.” The predicted price for LYRA in the upcoming period, according to Jefferies is $0.50 based on the research report published on May 07, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LYRA reach a price target of $2, previously predicting the price at $12. The rating they have provided for LYRA stocks is “Neutral” according to the report published on May 07th, 2024.
LYRA Trading at 325.19% from the 50-Day Moving Average
After a stumble in the market that brought LYRA to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 43.78% of gains for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LYRA starting from Waksal Harlan, who proposed sale 145,370 shares at the price of $0.10 back on Apr 25 ’25. After this action, Waksal Harlan now owns shares of Lyra Therapeutics Inc, valued at $14,930 using the latest closing price.
Palasis Maria, the Officer of Lyra Therapeutics Inc, proposed sale 39,567 shares at $0.09 during a trade that took place back on Apr 09 ’25, which means that Palasis Maria is holding shares at $3,545 based on the most recent closing price.
Stock Fundamentals for LYRA
Current profitability levels for the company are sitting at:
- -68.92 for the present operating margin
- -10.19 for the gross margin
The net margin for Lyra Therapeutics Inc stands at -67.11. The total capital return value is set at -1.82. Equity return is now at value -195.46, with -80.40 for asset returns.
Based on Lyra Therapeutics Inc (LYRA), the company’s capital structure generated 0.9 points at debt to capital in total, while cash flow to debt ratio is standing at -1.69.
Currently, EBITDA for the company is -60.26 million with net debt to EBITDA at -0.04. When we switch over and look at the enterprise to sales, we see a ratio of 27.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.96.
Conclusion
In a nutshell, Lyra Therapeutics Inc (LYRA) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
